Syapse

303 2nd Street, Sixth Floor, Suite 650, San Francisco, CA 94107, United States All United States companies → — Founded 2008

Healthcare Analytics / BI Specialty-Focused AI

Hematology Oncology

Oncology AI

Acquired/Merged (formerly VC-backed)

Website Claim this company

Products

Syapse Precision Medicine

Syapse

Oncology AI

Syapse Precision Medicine is an AI tool designed to support the clinical implementation of precision oncology. It is primarily for oncologists and healthcare systems, including academic and community cancer centers. [3, 7, 9] What it does: The platform integrates clinical and genomic data to provide insights at the point of care. [3, 8, 9] It […]

See all 1 product →

About Syapse

Syapse is a healthcare AI company focused on advancing precision medicine, particularly in oncology, by leveraging real-world evidence. The company’s platform integrates fragmented clinical, molecular, treatment, and health outcomes data from electronic health records and genomic information. This comprehensive data is then delivered to physicians at the point of care, enabling oncologists, healthcare systems, life sciences companies, and regulators to make more informed decisions and deliver personalized care.

Syapse’s mission is to extinguish the fear and burden of serious disease by transforming real-world evidence into actionable insights that directly impact patient care. They work with leading health systems, life sciences companies, and regulators to improve outcomes for cancer patients through their Learning Health Network. This network aims to make precision medicine a routine part of cancer care, ensuring that every patient benefits from treatments tailored to their full clinical and genomic profile. The company’s efforts are geared towards enabling health systems to scale precision oncology and fostering data collaboration to accelerate therapies and improve outcomes.

What Physicians Need to Know

Specialization

Syapse specializes in precision medicine and oncology, focusing on transforming real-world evidence into actionable patient insights. They aggregate and structure clinical, genomic, and treatment data to support cancer care teams.

Key Differentiators

Syapse's key differentiators include their focus on integrating diverse oncology data (EHRs, genomic data, molecular, pathology, radiology) to enable clinical decision-making and support molecular tumor boards. They also emphasize democratizing access to clinical trials for community cancer patients.

Technology Stack

Syapse utilizes cloud and data science tooling, including Azure and SageMaker, along with container orchestration (Kubernetes) and automation (Terraform, Jenkins). Their platform is cloud-based and works on AWS. They use an AI-enhanced data platform called Raydar to process and organize real-world data.

Acquisition and Integration

Syapse was acquired by N-Power Medicine in late 2024/early 2025. This integration aims to establish a large community-based prospective clinical research network, combining Syapse's network of community health systems and oncologists with N-Power's AI-enabled point-of-care platform.

Physician Tip

For physicians, Syapse's platform (now integrated with N-Power Medicine) provides a clinical decision resource that aggregates patient treatment and outcomes data, enabling independent clinical judgments. It integrates oncology data from electronic health records with genomic data to help search for specific gene mutations, synthesize treatment plans, compare patient outcomes, and find matching clinical trials. The platform is designed to be accessible within EHR systems, streamlining workflows. This can lead to more evidence-driven precision medicine and improved access to clinical trials for patients in community settings.

Syapse's technology stack suggests readiness for integration with enterprise data platforms and EHR/CRM ecosystems. Their platform integrates with electronic health records and genomic databases, and they have formed partnerships with various oncology-focused organizations and research groups. The acquisition by N-Power Medicine further expands their integrated network and capabilities for clinical research and patient care workflows.

At a glance

Founded 2008

HQ 303 2nd Street, Sixth Floor, Suite 650, San Francisco, CA 94107, United States · United States

CEO Ken Tarkoff

Funding Acquired/Merged (formerly VC-backed)

Products 1

Visit site

Products by Syapse

1 product in the directory

Syapse Precision Medicine

Syapse

Oncology AI

What the Web Says

Syapse is a company focused on empowering healthcare organizations with patient insights, particularly in cancer care. While there's limited information specifically on 'Syapse' products on major review sites like G2 and Capterra, there are several employee reviews available on platforms like Comparably and Indeed. It's important to note that many search results for 'Synapse' (a common misspelling or similar company name) refer to different entities, including a biopharma intelligence platform, a medical group, a software for gaming peripherals, and even a nootropic drink, so care has been taken to focus on 'Syapse' where possible.

Overall: Mixed

Strengths

Competitive compensation and good healthcare benefits for employees.
Opportunities for socialization among employees.
Emphasis on active, transparent partnerships with healthcare organizations.
Focus on delivering complete patient insights to drive impact for cancer patients.
Values include 'Customer First' and 'One Team'.

Limitations

Limited public product reviews for 'Syapse' specifically on major IT review sites.
Some employee reviews for similarly named companies (Synapse) mention being overwhelmed, understaffed, and lacking organization.
Potential for confusion with other companies named 'Synapse' offering different products and services.
One review for a 'Synapse' product mentioned it being behind on UX design and initially hard to use.

Based on reviews from: Comparably, Indeed.com, G2, Reddit, Elion Health, Trustpilot, BevNET.com

Last updated: 2026-10-21

Videos

News, demos, and interviews about Syapse.

Loading videos...

Videos load interactively. If none appear, search YouTube for Syapse →

View all on YouTube

Press & Coverage

Business Wire

N-Power Medicine Acquires Syapse to Expand Its Next-Generation Community-Based Network for Oncology Clinical Research and Clinical Trials

N-Power Medicine acquired Syapse Holdings Inc. in a stock-for-stock exchange on December 30, 2024. This acquisition aims to expand N-Power's community-based network for oncology clinical research and trials, integrating Syapse's network of over 1,000 oncologists and its data and technology stack.

2025-01

Clinical Trials Arena

Signal: FDA renews Syapse collaboration to use real-world data in oncology

The US FDA has renewed a four-year collaboration agreement with Syapse, a real-world data-focused healthcare company. The partnership focuses on evaluating real-world data study designs and methods to inform regulatory objectives.

2023-12

BioSpace

Syapse Enters Real-World Data Collaboration with Merck to Inform and Improve Cancer Care

Syapse announced a research collaboration with Merck to leverage real-world data (RWD) to generate high-quality insights, impacting patient care and advancing oncology research. This partnership aims to bring together expertise in RWE, insights application, clinical care, and life science innovation.

2021-10

GlobeNewswire

Syapse Expands Strategic Collaboration with Pfizer Focusing on Real-World Evidence

Syapse renewed its strategic collaboration with Pfizer to use real-world data from the Syapse Learning Health Network to understand treatment patterns, disease progression, and the overall treatment journey in oncology. This collaboration informs and enhances Pfizer's clinical studies.

2021-03

Healthcare IT News

FDA partners with Syapse to study regulatory use of real-world evidence

The U.S. Food and Drug Administration's Oncology Center of Excellence entered a multi-year research partnership with Syapse to explore how real-world evidence can better support regulatory decisions in oncology. The collaboration will examine testing and treatment patterns, dosing, safety, and oncology outcomes.

2019-08

PR Newswire

Amgen And Syapse Enter Precision Medicine Collaboration In Oncology

Amgen and Syapse announced a collaboration in precision medicine in oncology to identify eligible patients within the Syapse Learning Health Network for Amgen-sponsored clinical trials and bring these trials to community health system sites. Amgen will also gain access to real-world evidence for potential use in regulatory filings.

2019-05

Becker's Hospital Review

Syapse establishes precision medicine council

Syapse created a precision medicine council comprising oncology, operations, and research healthcare leaders from various health systems. The council will meet annually to discuss strategies and insights for developing precision medicine programs in community settings.

2018-06

PR Newswire

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology

Syapse and Roche announced a multi-year strategic collaboration to develop software products and analytics solutions. The goal is to empower healthcare providers with tools and insights for precision medicine at scale, focusing on improving patient outcomes and health-related quality of life.

2018-01

Frequently Asked Questions

What specific AI-powered products or solutions does Syapse offer for oncology, and how do they integrate with existing clinical workflows?

Syapse offers a Precision Medicine Platform that uses AI to integrate and analyze real-world data from various sources, including EHRs, to provide actionable insights for cancer care. The platform aims to help identify optimal treatments, match patients to clinical trials, and improve care coordination. It is designed to integrate with existing clinical systems to minimize disruption and enhance decision-making at the point of care.

How does Syapse ensure the privacy and security of patient data, and what compliance standards (e.g., HIPAA, GDPR) do your AI solutions adhere to?

Syapse prioritizes patient data privacy and security through robust technical and administrative safeguards. Their solutions are designed to be compliant with major healthcare regulations such as HIPAA in the United States and GDPR in Europe, ensuring that patient information is handled with the utmost care and in accordance with legal requirements. They employ data de-identification and strict access controls to protect sensitive health information.

What is the typical pricing model for Syapse's AI solutions, and are there different tiers or subscription options available for various sizes of healthcare organizations?

While specific pricing models are often customized based on the size and needs of the healthcare organization, Syapse typically offers subscription-based models for its Precision Medicine Platform. These models may vary depending on the scope of implementation, the number of users, and the specific modules or functionalities required. It is recommended to contact Syapse directly for detailed pricing information tailored to your institution.

What kind of technical support and clinical training does Syapse provide to ensure effective implementation and ongoing utilization of its AI platforms by medical staff?

Syapse provides comprehensive support, including technical assistance and clinical training, to ensure seamless implementation and effective utilization of its AI platforms. This typically includes onboarding programs, ongoing technical support, and educational resources to help medical staff understand and leverage the platform's capabilities. The goal is to empower healthcare professionals to confidently integrate the technology into their daily practice.

Can you describe Syapse's key partnerships with other healthcare technology companies, research institutions, or pharmaceutical companies, and how these collaborations benefit your clients?

Syapse has established partnerships with various healthcare stakeholders, including health systems, life sciences companies, and research institutions. These collaborations aim to expand the utility of their platform, enrich their real-world data insights, and accelerate the development of precision medicine. These partnerships ultimately benefit clients by providing access to a broader network of expertise, enhanced data sets, and more comprehensive solutions for cancer care.

What is the long-term vision and financial stability of Syapse as a company, and how does this assure continued support and innovation for its AI products?

Syapse is committed to advancing precision medicine in oncology through continuous innovation and strategic growth. The company has secured significant funding rounds and has a clear vision for expanding its platform's capabilities and reach. This financial stability and long-term vision are intended to assure clients of sustained product development, ongoing support, and a commitment to remaining a leader in the healthcare AI space.

How does Syapse's AI platform handle the evolving landscape of cancer treatments and new data types, ensuring its recommendations remain current and evidence-based?

Syapse's AI platform is designed with adaptability in mind, continuously integrating new research, clinical guidelines, and emerging data types to keep its recommendations current and evidence-based. The platform leverages real-world data, which includes the latest treatment outcomes and patient responses, to refine its algorithms. This dynamic approach ensures that the insights provided reflect the most up-to-date understanding of cancer care.

Investors

Who's funded Syapse.

Koa Labs

VC T3

Cambridge, United States

$250k-$1M

Koa Labs is a small early-stage investment platform with limited public information about fund size, partner team, and detailed thesis. Public footprint…

AI/ML in Healthcare Care Delivery / Tech-Enabled Services

Related Companies

Suggest an Edit → | Report an issue